Evidence map›Paper›PMID 29299132›Full record

ArticleOncotarget2017

Saikosaponins A, C and D enhance liver-targeting effects of anticancer drugs by modulating drug transporters.

Limin Feng, Lijuan Liu, Ya Zhao, Ruizhi Zhao

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020
    Article
  4. Effects of Animal Strain, Dose, and Cotreatment with Saikosaponin bEuropean journal of drug metabolism and pharmacokinetics · 2019
    Article
  5. Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Article
  6. A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Limin FengSecond Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Lijuan LiuSecond Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Ya ZhaoSecond Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Ruizhi ZhaoSecond Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Guangzhou University of Chinese Medicine · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vinegar-baked Radix Bupleuri (VBRB) is clinically used to enhance the pharmacological activity of drugs used to treat liver diseases. Our previous study demonstrated that this effect is dependent on increased drug accumulation in the liver; however, the underlying mechanism remains unclear. We hypothesize that VBRB mediated its effects by altering drug transporters. Thus, the present study was designed to determine the effects of VBRB's main components, saikosaponin A, C, and D, on drug transporters. Transporter activity was determined by measuring the intracellular concentration of transporter substrates. Protein and mRNA levels were measured by Western blot and qPCR, respectively. Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Saikosaponin A, C, and D differentially affected transporter activity. All of the saikosaponins inhibited Pgp activity in Pgp over-expressing HEK293 cells and increased substrate uptake of OCT2 in OCT2 over-expressing HEK293. Saikosaponin C and D inhibited MRP2 activity in HEK293 cells and BRL 3A cell with high MRP2 expression; saikosaponin A increased colchicine accumulation in GSH-stimulated HEK293 cells, but decreased colchicine uptake in HEK293 cells. Saikosaponin D inhibited MRP1 activity in GSH-stimulated HEK293 cells, but marginally affected the uptake of colchicine in HEK293 cells. In conclusion, saikosaponins play a role in VBRB's induced liver targeting effect through affecting drug transporters with a transporter expression amount depending manner.

Indexed as

MRP1MRP2OCT2Pgpsaikosaponin

Identifiers

PMID29299132
PMCPMC5746367
OpenAlexW2768629629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.